Free Trial
NASDAQ:GYRE

Gyre Therapeutics (GYRE) Stock Price, News & Analysis

Gyre Therapeutics logo
$9.44 -0.74 (-7.27%)
Closing price 04:00 PM Eastern
Extended Trading
$9.80 +0.36 (+3.76%)
As of 05:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Gyre Therapeutics Stock (NASDAQ:GYRE)

Key Stats

Today's Range
$9.26
$10.45
50-Day Range
$6.41
$11.50
52-Week Range
$6.11
$19.00
Volume
469,726 shs
Average Volume
113,955 shs
Market Capitalization
$885.08 million
P/E Ratio
472.00
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Buy

Company Overview

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Gyre Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
6th Percentile Overall Score

GYRE MarketRank™: 

Gyre Therapeutics scored higher than 6% of companies evaluated by MarketBeat, and ranked 915th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Gyre Therapeutics is 469.85, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.86.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Gyre Therapeutics is 469.85, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.88.

  • Price to Book Value per Share Ratio

    Gyre Therapeutics has a P/B Ratio of 52.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Gyre Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    13.99% of the float of Gyre Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Gyre Therapeutics has a short interest ratio ("days to cover") of 15.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Gyre Therapeutics has recently decreased by 5.20%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Gyre Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Gyre Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.99% of the float of Gyre Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Gyre Therapeutics has a short interest ratio ("days to cover") of 15.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Gyre Therapeutics has recently decreased by 5.20%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Gyre Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for Gyre Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for GYRE on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Gyre Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $157,124.00 in company stock.

  • Percentage Held by Insiders

    19.52% of the stock of Gyre Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 23.99% of the stock of Gyre Therapeutics is held by institutions.

  • Read more about Gyre Therapeutics' insider trading history.
Receive GYRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GYRE Stock News Headlines

Gyre Therapeutics announces new stock offering
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

GYRE Stock Analysis - Frequently Asked Questions

Gyre Therapeutics' stock was trading at $12.10 at the beginning of the year. Since then, GYRE stock has decreased by 22.1% and is now trading at $9.42.
View the best growth stocks for 2025 here
.

Gyre Therapeutics, Inc. (NASDAQ:GYRE) posted its earnings results on Friday, May, 9th. The company reported $0.03 earnings per share for the quarter, meeting analysts' consensus estimates of $0.03. The company had revenue of $22.06 million for the quarter, compared to analyst estimates of $28.40 million. Gyre Therapeutics had a negative net margin of 84.57% and a negative trailing twelve-month return on equity of 118.43%.

Top institutional shareholders of Gyre Therapeutics include SBI Securities Co. Ltd. (0.13%), Charles Schwab Investment Management Inc. (0.12%), American Century Companies Inc. (0.03%) and Bank of New York Mellon Corp (0.02%). Insiders that own company stock include Songjiang Ma and Nassim Usman.
View institutional ownership trends
.

Shares of GYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gyre Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Palo Alto Networks (PANW) and Invesco QQQ (QQQ).

Company Calendar

Last Earnings
5/09/2025
Today
5/28/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GYRE
Previous Symbol
NASDAQ:GYRE
Employees
40
Year Founded
N/A

Profitability

Trailing P/E Ratio
474.25
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$92.93 million
Pretax Margin
-74.10%

Debt

Sales & Book Value

Annual Sales
$100.64 million
Cash Flow
$0.19 per share
Price / Cash Flow
50.49
Book Value
$0.18 per share
Price / Book
52.69

Miscellaneous

Free Float
75,266,000
Market Cap
$889.29 million
Optionable
No Data
Beta
1.90
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:GYRE) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners